



A.P. Pharma Closes \$40 Million Common Stock Offering; Underwriters Exercise Full over-Allotment Option

June 19, 2007

REDWOOD CITY, Calif.--(BUSINESS WIRE)--June 19, 2007--A.P. Pharma, Inc. (NASDAQ:APPA, temporarily traded under the symbol "APPAD" until June 25, 2007 to reflect the recent reverse stock split), a specialty pharmaceuticals company, today announced the completion of a public offering of 24,393,939 shares of its common stock at a public offering price of \$1.65 per share, including 3,181,818 shares sold pursuant to the full exercise of an over-allotment option granted to the underwriters. Proceeds from this offering are intended to be used for clinical development of APF530, the Company's lead product candidate; development and clinical testing of our other product candidates; and for working capital, capital expenditures and other general corporate purposes.

Merriman Curhan Ford & Co. acted as the sole book-running manager in this offering, and Dawson James Securities, Inc. acted as co-manager. Copies of the final prospectus may be obtained from Merriman Curhan Ford & Co. by phone at 415-248-5600, by fax at 415-248-5690, or by mail at Merriman Curhan Ford & Co., 600 California Street, 9th Floor, San Francisco, CA 94108.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About A.P. Pharma

A.P. Pharma is a specialty pharmaceutical company focused on the development of ethical (prescription) pharmaceuticals utilizing its proprietary polymer-based drug delivery systems. The Company's primary focus is the development and commercialization of its bioerodible injectable and implantable systems under the trade name Biochronomer(TM). Initial target areas of application for the Company's drug delivery technology include anti-nausea, pain management, anti-inflammation and DNA/RNAi applications. For further information visit the Company's web site at www.appharma.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Reform Act of 1995. These forward-looking statements involve risks and uncertainties including uncertainties associated with regaining compliance with NASDAQ rules, timely development, approval, launch and acceptance of new products, satisfactory completion of clinical studies, establishment of new corporate alliances, progress in research and development programs and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. We caution investors that forward-looking statements reflect our analysis only on their stated dates. We do not intend to update them except as required by law.

CONTACT: Company Contacts:

A.P. Pharma, Inc.
Gregory Turnbull
President and Chief Executive Officer
(650) 366-2626

or
Michael O'Connell
Chief Financial Officer and
Chief Operating Officer
(650) 366-2626

or
Investor Relations Contact:
Lippert/Heilshorn & Associates
Don Markley
(310) 691-7100
dmarkley@lhai.com

SOURCE: A.P. Pharma, Inc.